Skandinaviska Enskilda Banken Ab (Publ) Chemo Centryx, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

  • $21.5 Billion
  • Q3 2024

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$22.17 - $51.8 $443,400 - $1.04 Million
20,000 New
20,000 $1.03 Million
Q2 2021

Aug 10, 2021
SELL
$9.59 - $50.88 $173,320 - $919,554
-18,073 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$49.53 - $68.4 $726,753 - $1 Million
14,673 Added 431.56%
18,073 $926,000
Q4 2020

Feb 11, 2021
BUY
$47.25 - $65.16 $56,700 - $78,192
1,200 Added 54.55%
3,400 $211,000
Q3 2020

Nov 12, 2020
SELL
$46.35 - $61.69 $292,005 - $388,647
-6,300 Reduced 74.12%
2,200 $121,000
Q2 2020

Aug 13, 2020
BUY
$38.58 - $65.07 $327,930 - $553,095
8,500 New
8,500 $489,000

Others Institutions Holding CCXI

# of Institutions
6
Shares Held
66.3K
Call Options Held
0
Put Options Held
0
View Full List

About ChemoCentryx, Inc.

CCXI Quotes by TradingView
  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Skandinaviska Enskilda Banken Ab (Publ) Portfolio

Follow Skandinaviska Enskilda Banken Ab (Publ) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

News

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email